FibroGen Announces Three Scientific Publications Highlighting Important Medical Device and Pharmaceutical Uses of Recombinant Human Collagens and Gelatins.Business Editors/Health/Medical Writers BIOWIRE2K SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--April 1, 2004 Company Also Announces Presentation and Exhibition Schedule FibroGen, Inc., today announced the recent publication of three scientific articles featuring hemostatic hemostatic /he·mo·stat·ic/ (he?mo-stat´ik) 1. causing hemostasis, or an agent that so acts. 2. due to or characterized by stasis of the blood. he·mo·stat·ic adj. , drug delivery, and tissue engineering applications of the Company's proprietary recombinant human collagens and gelatins. Produced using fully synthetic and reproducible processes, FibroGen's recombinant collagens and gelatins provide highly pure and fully characterized replacements for animal-sourced collagen and gelatin gelatin or animal jelly, foodstuff obtained from connective tissue (found in hoofs, bones, tendons, ligaments, and cartilage) of vertebrate animals by the action of boiling water or dilute acid. in a variety of medical device and pharmaceutical applications. The Company also announced its 2004 presentation and exhibition schedule. Master File applications are in preparation for FibroGen's recombinant human collagen type III Type III may stand for:
Reprint requests should be directed to FibroGen for the following articles: -- Yang C, Hillas P, Tang J, Balan J, Notbohm H, Polarek J. Development of a recombinant human collagen-type III based hemostat hemostat /he·mo·stat/ (he´mo-stat) 1. a small surgical clamp for constricting blood vessels. 2. an antihemorrhagic agent. he·mo·stat n. 1. . J Biomed Mater Res. 2004 Apr 15;69B(1):18-24. -- Yang C, Hillas PJ, Baez JA, Nokelainen M, Balan J, Tang J, Spiro R, Polarek JW. The application of recombinant human collagen in tissue engineering. BioDrugs. 2004;18(2):103-19. -- Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, Carmichael D, Perala M, Hamalainen ER, Jarvinen M, Polarek J. Recombinant collagen and gelatin for drug delivery. Adv Drug Deliv Rev. 2003 Nov 28;55(12):1547-67. FibroGen's 2004 presentation and exhibition schedule includes: -- 227th American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in National Meeting, Anaheim, CA, March 28 - April 1 -- 7th World Biomaterials Congress, Sydney, Australia, May 17 - 21 -- 7th Annual Conference on Vaccine Research, Arlington, VA, May 24 - 26 -- 2nd Pharmaceutical Sciences World Congress, Kyoto, Japan, May 29 - June 3 -- American Association American Association refers to one of the following professional baseball leagues:
MD, November 7 - 11 About FibroGen FibroGen, Inc., is a privately held biotechnology company focused on the discovery, development, and commercialization of therapeutics, recombinant human collagens, and recombinant gelatins to address unmet needs in the medical, pharmaceutical, and consumer markets. FibroGen's therapeutic target areas include fibrosis, anemia, and ischemia Ischemia Definition Ischemia is an insufficient supply of blood to an organ, usually due to a blocked artery. Description Myocardial ischemia is an intermediate condition in coronary artery disease during which the heart tissue is . For more information about FibroGen, Inc., please visit www.fibrogen.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion